• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cases Journal >Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
【24h】

Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report

机译：HER2阳性乳腺癌的眼转移及对紫杉醇和曲妥珠单抗联合治疗的反应：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose Breast cancer is the most common tumour to metastasize to the uveal tract. The mean survival period after diagnosis of metastasis to the eye, ranges from 10 to 32 months. However, recent advances in therapy including the use of monoclonal antibody therapy, will hopefully improve treatment outcomes and prolong survival rates. Methods We report a case of a 45 year old woman with a HER2 positive breast cancer, who developed two metastatic lesions in the left choroid, and the left optic nerve sheath. She underwent treatment with a combination of chemotherapy (Paclitaxel) and anti-HER2 monoclonal antibodies (Trastuzumab). Results Nine months after treatment, a B-scan showed resolution of the superior choroidal focus, as well as absence of blood flow within the optic nerve sheath. The inferonasal lesion was still present but the dimensions were reduced. Conclusion The patient underwent a combined treatment of chemotherapy and Trastuzumab to increase the response rate. Trastuzumab is a humanized monoclonal antibody, which binds to the extracellular segment of the HER2eu receptor. Nine months following the therapy her vision was stable, whilst one focus of the tumour in the affected eye, had regressed. The favourable response highlights the significant impact of this new therapy, as an alternative to external beam radiotherapy in patients with ocular metastasis from HER2 (+) breast cancer.
机译：目的乳腺癌是最常见的转移至葡萄膜的肿瘤。诊断为眼转移后的平均生存期为10到32个月。但是，包括单抗治疗在内的近期治疗进展有望改善治疗效果并延长生存率。方法我们报道了一名HER2阳性乳腺癌的45岁女性，该患者在左脉络膜和左视神经鞘膜上发生了两个转移性病变。她接受了化疗（紫杉醇）和抗HER2单克隆抗体（曲妥珠单抗）的联合治疗。结果治疗9个月后，B扫描显示上脉络膜上焦灶消失，视神经鞘内无血流。鼻下病变仍存在，但尺寸减小。结论该患者接受了化疗和曲妥珠单抗的联合治疗，以提高缓解率。曲妥珠单抗是人源化单克隆抗体，可与HER2 / neu受体的细胞外区段结合。治疗后九个月，她的视力稳定，而患病眼中的一个肿瘤灶已消退。良好的反应凸显了这种新疗法的重大影响，它可以替代HER2（+）乳腺癌眼外转移患者的体外放射疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号